Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned?

ABSTRACT: The use of different pathways in the treatment of rheumatoid arthritis has led to a significant decrease in the number of treatment-resistant patients. In this context, interleukin (IL)-6 inhibition has filled an important gap in rheumatoid arthritis treatment with its effectiveness and safety in both monotherapy and combinations. The process of IL-6 inhibition initiated with IL-6 receptor blockers has prompted questions regarding the potential impact and safety of different inhibitions of this pathway, such as the direct blockade of IL-6. Following the termination of the development of sirukumab because of mortality data in early studies, the investigation of olokizumab, which targets a different region of the IL-6 cytokine, has renewed the hope in this area and the safety concerns have b

SUBMITTER: Avci AB 

PROVIDER: S-EPMC10789669 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature